Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Nitric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3E | A5X5Y0 | 7/20 | 0.48 |
| ▸ | HTR3B | O95264 | 7/20 | 0.48 |
| ▸ | HTR3A | P46098 | 7/20 | 0.48 |
| ▸ | HTR3D | Q70Z44 | 7/20 | 0.48 |
| ▸ | HTR3C | Q8WXA8 | 7/20 | 0.48 |
| ▸ | PLAU | P00749 | 5/20 | 0.47 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.45 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.45 |
| ▸ | SLC22A3 | O75751 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | NOS1 | P29475 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nitric Acid SCHEMBL13739226 | 0.88 | HTR3E (0.42) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| Nitric Acid SCHEMBL1665 | 0.88 | TSHR (0.53) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL27886596 | 0.85 | HTR3E (0.61) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| Nitric Acid SCHEMBL7813484 | 0.82 | HTR3E (0.77) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| Nitric Acid SCHEMBL28348863 | 0.78 | TSHR (0.62) | TSHRGPR35KDM4EMEN1ALDH1A1 | |
| Nitric Acid SCHEMBL6033747 | 0.77 | PLAU (0.47) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| Nitric Acid SCHEMBL6034160 | 0.77 | PLAU (0.47) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| Nitric Acid SCHEMBL6953528 | 0.77 | HTR3E (0.53) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| Nitric Acid SCHEMBL6980748 | 0.74 | HTR3E (0.53) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| Nitric Acid SCHEMBL11561556 | 0.74 | PLAU (0.49) | HTR3EHTR3BHTR3AHTR3DHTR3C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1605946-B1 | THIAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMA (US) | 2008-05-28 | — | — | EP | disclosed |
| US-7276502-B2 | Thiazoles useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-10-02 | — | — | US | disclosed |
| EP-1605946-A2 | THIAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES | Vertex Pharmaceuticals Incorporated (US) | 2005-12-21 | — | — | EP | disclosed |
| US-20050004150-A1 | For therapy and prophylaxis of immunodeficiency disorders, inflammatory diseases, allergic diseases, autoimmune diseases, proliferative disorders, immunologically-mediated diseases, or respiratory disorders | VERTEX PHARMACEUTICALS INCORPORATED | 2005-01-06 | — | — | US | disclosed |
| WO-2004087699-A2 | THIAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2004-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004150-A1 | For therapy and prophylaxis of immunodeficiency disorders, inflammatory diseases, allergic diseases, autoimmune diseases, proliferative disorders, immunologically-mediated diseases, or respiratory disorders | TSLP, JAK1, SERPINB1 | HTR3E 4031/4885HTR3B 4083/4885HTR3A 4233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.